ST
The startup develops a cell-based therapy utilizing neonatal cardiac progenitor cells sourced from discarded tissue during heart surgeries in infants with congenital conditions. This therapy targets heart attack patients and those with advanced heart failure, providing a potential treatment option for severe cardiac dysfunction.
Updated 3 months ago
Funding
$28.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a cell-based therapy utilizing neonatal cardiac progenitor cells sourced from discarded tissue during heart surgeries in infants with congenital conditions. This therapy targets heart attack patients and those with advanced heart failure, providing a potential treatment option for severe cardiac dysfunction.